Article info
Current controversy
The unethical use of ethical rhetoric: the case of flibanserin and pharmacologisation of female sexual desire
- Correspondence to Weronika Chańska, Department of Philosophy and Bioethics, Jagiellonian University Medical College, Kraków, Poland; weronika.chanska{at}uj.edu.pl
Citation
The unethical use of ethical rhetoric: the case of flibanserin and pharmacologisation of female sexual desire
Publication history
- Received February 18, 2016
- Revised April 9, 2016
- Accepted May 18, 2016
- First published June 8, 2016.
Online issue publication
October 25, 2016
Article Versions
- Previous version (8 June 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Hypoactive sexual desire disorder: inventing a disease to sell low libido
- Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent
- Non-pharmacological interventions for treating sexual dysfunction in postpartum women: a systematic review protocol
- Sexual dysfunction in women with HIV
- Sexual dysfunction and commonly used drugs in neurology
- What are the prevalence and factors associated with sexual dysfunction in breastfeeding women? A Brazilian cross-sectional analytical study
- Merging of marketing and medical science: female sexual dysfunction
- A practical approach to assessing and managing sexual dysfunction in multiple sclerosis
- Testosterone patches for female sexual dysfunction
- Female low sexual desire and sexually transmitted infections